First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05438329. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05438329
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 1,123 participants
Conditions and interventions
Conditions
Interventions
- BNT327 Drug
- DB-1305/BNT325 Drug
- Pembrolizumab Combination Product
Drug · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 18, 2022
- Primary completion
- Aug 12, 2027
- Completion
- Sep 9, 2027
- Last update posted
- May 11, 2026
2022 – 2027
United States locations
- U.S. sites
- 42
- U.S. states
- 18
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 139 | Bullhead City | Arizona | 86442 | — |
| Site 103 | Cerritos | California | 90703 | — |
| Site 136 | La Jolla | California | 92093 | — |
| Site 127 | Los Angeles | California | 90027 | — |
| Site 133 | Los Angeles | California | 90067 | — |
| Site 108 | Los Angeles | California | 90404 | — |
| Site 131 | Washington D.C. | District of Columbia | 20007 | — |
| Site 122 | Coral Springs | Florida | 33065 | — |
| Site 142 | Hialeah | Florida | 33013 | — |
| Site 114 | Margate | Florida | 33063 | — |
| Site 120 | Miami | Florida | 33133 | — |
| Site 126 | Ocala | Florida | 34474 | — |
| Site 140 | Orange City | Florida | 32763 | — |
| Site 109 | Plantation | Florida | 33322 | — |
| Site 141 | St. Petersburg | Florida | 33709 | — |
| Site 117 | Tamarac | Florida | 33321 | — |
| Site 111 | Honolulu | Hawaii | 96813 | — |
| Site 134 | Chicago | Illinois | 60611 | — |
| Site 124 | Dearborn | Michigan | 48126 | — |
| Site 106 | Detroit | Michigan | 48201 | — |
| Site 125 | Royal Oak | Michigan | 48073 | — |
| Site 129 | Las Vegas | Nevada | 89106 | — |
| Site 160 | Mineola | New York | 11501 | — |
| Site 116 | New York | New York | 10016 | — |
| Site 102 | New York | New York | 10065 | — |
| Site 130 | Westbury | New York | 11590 | — |
| Site 121 | Wilson | North Carolina | 27895 | — |
| Site 101 | Canton | Ohio | 44718 | — |
| Site 132 | Cincinnati | Ohio | 45219 | — |
| Site 118 | Oklahoma City | Oklahoma | 73104 | — |
| Site 123 | Philadelphia | Pennsylvania | 19107 | — |
| Site 112 | Pittsburgh | Pennsylvania | 15224 | — |
| Site 105 | Nashville | Tennessee | 37203 | — |
| Site 110 | Arlington | Texas | 76017 | — |
| Site 104 | Houston | Texas | 77030 | — |
| Site 115 | Houston | Texas | 77074 | — |
| Site 119 | Tyler | Texas | 75701 | — |
| Site 107 | Fairfax | Virginia | 22031 | — |
| Site 135 | Falls Church | Virginia | 19107 | — |
| Site 128 | Tacoma | Washington | 98405 | — |
| Site 138 | Tacoma | Washington | 98405 | — |
| Site 137 | Sheboygan | Wisconsin | 53081 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
Recently updated Advanced Solid Tumor trials
Other public records listing Advanced Solid Tumor. Sorted by last update posted; newest first. Not a recommendation.
- NCT07751042: Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab Recruiting
- NCT07749586: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting
- NCT07602842: A Study of IDP-001 in Advanced or Metastatic Solid Tumors Recruiting
- NCT06545942: Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors Recruiting
- NCT06244485: A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Active, not recruiting
- NCT05098132: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05438329, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2026 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05438329 live on ClinicalTrials.gov.